Pfizer Vaccines, Collegeville, PA 19426–3982, USA.
Clin Infect Dis. 2012 Jul;55(2):259-64. doi: 10.1093/cid/cis359. Epub 2012 Apr 11.
A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥ 50 years to compare the immune response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the standard of care over the past 30 years. The results demonstrate that adults, regardless of whether they are naive or previously vaccinated with the polysaccharide vaccine, have an overall superior antibody response when vaccinated with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine. More importantly, the nature of the response is indicative of a T-cell-dependent response that elicits immunological memory and, therefore, primes the immune system for either natural exposure or subsequent booster vaccination with either conjugate or polysaccharide vaccine. The conjugate vaccine, which has been successful in reducing pneumococcal disease in children, now provides a new approach to preventing pneumococcal disease, including community-acquired pneumonia, in adults.
一种 13 价肺炎球菌结合疫苗已在年龄≥50 岁的成年人中进行了研究，以比较其免疫反应与过去 30 年来一直作为标准护理的 23 价肺炎球菌多糖疫苗的免疫反应。结果表明，无论成年人是否为多糖疫苗的初免者或既往接种者，与肺炎球菌多糖疫苗相比，用结合疫苗进行免疫接种时，总体上具有更好的抗体反应。更重要的是，反应的性质表明是 T 细胞依赖性反应，可引起免疫记忆，从而为免疫系统对自然暴露或随后用结合疫苗或多糖疫苗进行加强免疫接种做好准备。这种结合疫苗在减少儿童肺炎球菌疾病方面取得了成功，现在为预防成年人肺炎球菌疾病（包括社区获得性肺炎）提供了一种新方法。
